Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2022 (Report dated August 2, 2022)
Principal Executive Offices: Tel Aviv, Israel
This filing reports a material corporate event: the execution of a clinical trial agreement with Yale University to conduct a Phase IIb trial for Tourette Syndrome.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on a specific corporate development rather than a periodic financial statement.
Material Changes
- Clinical Trial Agreement: On August 1, 2022, the Company signed an agreement with Yale University to conduct its Phase IIb clinical trial in Tourette Syndrome.
- Registration Statement Update: Specific paragraphs and the "Forward-Looking Statements" section of the associated press release (Exhibit 99.1) are incorporated by reference into the Company's active registration statements on Form F-3 and Form S-8.
Guidance, Outlook, and Risks
Outlook: The filing indicates progression in the Company's clinical development pipeline for Tourette Syndrome via the partnership with Yale University.
Risks and Contingencies: The filing references a "Forward-Looking Statements" section within the incorporated press release (Exhibit 99.1) but does not detail specific risks or contingencies within the body of this Form 6-K text.
Investor Verification Checklist
- Verify the specific terms and scope of the clinical trial agreement with Yale University by reviewing Exhibit 99.1 (Press Release dated August 1, 2022).
- Confirm the status of the Company's cash reserves and burn rate, as this filing does not contain updated financial data.
- Review the incorporated "Forward-Looking Statements" in the press release for specific risk factors related to the Phase IIb trial timeline and outcomes.
- Check subsequent filings for any updates on the initiation or progress of the Tourette Syndrome trial.